Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Bonadonna G, Zambette M and Valagussa P (1995) Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. JAMA 273: 542–547
Bos A, de Graf H, de Vries E, Piersma H and Willemse P (2000) Feasibility of a dose-intensive CMF regimen with granulocyte colony stimulating factor as adjuvant therapy in premenopausal patients with node-positive breast cancer. Br J Cancer 82: 1920–1924
Dombernowsky P, Gehl J, Boesgaard M, Jensen T, Jensen B and Ejlersen B (1995) Treatment of metastatic breast cancer with paclitaxel and doxorubicin. Semin Oncol 22: 13–17
EBCTCG (1998) Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 352: 930–942
Fisher B, Anderson S, DeCillis A, Dimitrov N, Atkins J, Fehrenbacher L, Henry P, Romond E, Lanier K, Davila E, Kardinal C, Laufman L, Pierce H, Abramson N, Keller A, Hamm J, Wickerham D, Begovic M, Tan-Chiu E, Tian W and Wolmark N (1999) Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: findings from the National Surgical Adjuvant Breast and Bowel Project B-25. J Clin Oncol 17: 3374–3388
Fisher B, Anderson S, Wickerham D, DeCillis A, Dimitrov N, Mamounas E, Wolmark N, Pugh R, Atkins J, Meyers F, Abramson N, Wolter J, Bornstein R, Levy L, Romond E, Caggiano V, Grimaldi M, Jochimsen P and Deckers P (1997) Increased intensification and total dose of cyclophosphamide in a doxorubicin-dyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol 15: 1858–1869
Gianni L, Munzone E, Capri G, Fulfaro F, Tarenzi E, Villani F, Spreafico C, Laffranchi A, Caraceni A, Martini C, Stefanelli M, Valagussa P and Bonadonna G (1995) Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose finding and sequence-finding study. J Clin Oncol 13: 2688–2699
Henderson I, Berry D, Demetri G, Cirrincione C, Goldstein L, Martino S, Ingle J, Cooper M, Canellos G, Borden E, Fleming G, Holland J, Graziano S, Carpenter J, Muss H and Norton L (1998) Improved disease-free and overall survival from the addition of sequential paclitaxel but not from the escalation of doxorubicin dose level in the adjuvant chemotherapy of patients with node-positive primary breast cancer. Proceedings of the Annual Meeting of the American Society of Clinical Oncology 17: 390a
Hudis C, Seidman A, Raptis G, Baselga J, Fennelly D, Theodoulou M, Gilewski T, Currie V, Moynahan M, Surbone A, Sklarin N, Robles M, Riccio L, Yao T-J Uhlenhopp M and Norton L (1996) Sequential dose-dense doxorubicin –> paclitaxel –> cyclophosphamide is less toxic than doxorubicin –> concurrent paclitaxel + cyclophosphamide as adjuvant therapy in resected node positive breast cancer. Proc Am Soc Clin Onc 15: 119
Hudis C, Fornier M, Riccio L, Lebwohl D, Crown J, Gilewski T, Surbone A, Currie V, Seidman A, Reichman B, Moynahan M, Raptis G, Sklarin N, Theodoulou M, Weiselberg L, Salvaggio R, Panageas K, Yao T and Norton L 1999 a) Five-year results of dose-intensive sequential adjuvant chemotherapy for women with high-risk node-positive breast cancer: a phase II study. J Clin Oncol 17: 1118–1126
Hudis C, Seidman A, Baselga J, Raptis G, Lebwohl D, Gilewski T, Moynahan M, Sklarin N, Fennelly D, Crown J, Surbone A, Uhlenhopp M, Riedel E, Yao T and Norton L 1999 b) Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high-risk breast cancer: feasibility and efficacy. J Clin Oncol 17: 93–100
Jain KK, Casper ES, Geller NL and Al E (1985) A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer. J Clin Oncol 3: 3818–3826
Lalisang R, Voest E, Wils J, Nortier H, Erdkamp F, Hillen H, Wals J, Schouten H and Blijham G (2000) Dose-dense epirubicin and paclitaxel with G-CSF: a study of decreasing intervals in metastatic breast cancer. Br J Cancer 82: 1914–1919
Lichtman S, Ratain M, Van Echo D, Egorin M, Budman D, Vogelzang N, Norton L, Rosner G and Schilsky R (1993) Phase I trial of granulocyte-macrophage colony stimulating factor (GM-CSF) plus high dose biweekly cyclophosphamide: a CALGB Study. J Natl Cancer Inst 85: 1319–1326
Norton L, Simon R, Brereton J and Bogden A (1976) Predicting the course of Gompertzian growth. Nature 264: 542–545
Skipper HE (1971) Kinetics of mammary tumor cell growth and implications for therapy. Cancer 28: 1479–1499
Valagussa P, Tancini G and Bonadonna G (1986) Salvage treatment of patients suffering relapse after adjuvant CMF chemotherapy. Cancer 58: 1411
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Hudis, C. Dose-dense chemotherapy for breast cancer: the story so far. Br J Cancer 82, 1897–1899 (2000). https://doi.org/10.1054/bjoc.2000.1198
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1198